ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
If you are not happy with the results below please do another search
The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
The Who’s Who of the biotech industry relies on Austria. Every second biotechnology company is located in the hotspot of Vienna, where a leading research centre the Campus Vienna BioCenter has emerged. Multinationals and startups benefit from an extensive value chain, from basic research to production and distribution. The national investment promotion agency Austrian Business Agency (ABA) is the first point of contact when making the leap into the Austrian market.
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Together with star investor Kleiner Perkins, Origenis GmbH, a privately held German biopharmaceutical company, successfully establishes its new business model for the clinical development of its neuroprotective drug pipeline. The formation and financing of Neuron23 Inc. was announced in South San Francisco.
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups. The 360-page publication describes the development of the Innovation and Start- up Center for Biotechnology into the leading biotechnology center in Europe
Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.